NORDIC NANOVECTOR AS: EXTRAORDINARY GENERAL MEETING ON 12 NOVEMBER 2014

The Board of Directors of Nordic Nanovector AS has resolved to call for an extraordinary general meeting (EGM) to be held on 12 November 2014 at 15:00 (CET) in the Company’s offices at Kjelsåsveien 168 B, 4th floor.
On the agenda for the EGM is inter alia conversion of the Company into a public limited company, Board and nomination committee elections and remuneration, instructions for the nomination committee and amendments to the Articles of Association.
The EGM notice with enclosures is sent to the shareholders today and is also attached to this press release.

INFORMATION

Luigi Costa, Chief Executive Officer                    

Cell: (+41) 79 124 8601                

E-mail: lcosta@nordicnanovector.com


Tone Kvåle, Chief Financial Officer

Cell: (+47) 91 51 95 76

E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com